A New N2 Descriptor for Resectable Non-Small Cell Lung Cancer: The Classification Based on Skip Metastasis and the...

Area of Science:

• Oncology
• Thoracic Surgery
• Cancer Research

Background:

• Non-small cell lung cancer (NSCLC) patient outcomes vary due to heterogeneous disease patterns.
• Skip mediastinal lymph node metastasis is a frequent occurrence and a key prognostic factor in N2 lung cancer.
• Current N2 classification may not fully capture prognostic differences in NSCLC.

Purpose of the Study:

• To evaluate the clinical significance and prognostic value of a novel N2 descriptor.
• To compare the efficacy of the new N2 descriptor against the ninth edition N2 classification.
• To analyze metastasis patterns and survival outcomes based on skip N2 disease.

Main Methods:

• Retrospective review of 533 patients with stage pN2 NSCLC.
• Classification of patients into three categories: skip N2a, skip N2b/nonskip N2a, and nonskip N2b.
• Analysis of clinical characteristics, survival outcomes (Overall Survival - OS, Disease-Free Survival - DFS), and lymph node metastasis patterns.

Main Results:

• Significant prognostic differences were observed between the subdivided N2 descriptor groups (p < 0.001 for OS and DFS between skip N2a vs. skip N2b/nonskip N2a; p = 0.037 for OS and p = 0.029 for DFS between skip N2b/nonskip N2a vs. nonskip N2b).
• The new N2 descriptor demonstrated superior prognostic value compared to the ninth edition N2 classification, indicated by a smaller Akaike Information Criterion and higher Harrell C-index.
• Patients with skip N2 metastasis exhibited better survival outcomes and distinct lymph node metastasis patterns compared to nonskip patients.

Conclusions:

• The new N2 descriptor is a more reliable and accurate prognostic determinant for NSCLC patients with N2 disease than the ninth N2 classification.
• This novel descriptor warrants consideration for future revisions of the tumor, node, and metastasis (TNM) staging system.
• The findings highlight the importance of considering skip N2 metastasis in NSCLC staging and treatment planning.